Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,946

Document Document Title
WO/2022/168939A1
Provided is a ceramide synthase gene expression promoting agent in which a prescribed dipeptide is employed as a main ingredient for bringing about a function, and which is capable of increasing the expression level of a ceramide synthas...  
WO/2022/165606A1
LIN28 is an RNA binding protein that binds and inhibits the expression and maturation of Iet7 microRNA that carries key tumor suppressor functions. Thus, LIN28 is a feasible and effective molecular target for directed inhibition with the...  
WO/2022/168894A1
[Problem] To provide a new material that prevents adhesion of pollutants by forming a film on a cloth or paper surface, and that prevents the cloth and paper surfaces from being polluted by the pollutants. [Solution] An anti-pollution ma...  
WO/2022/168872A1
A cell culture microcarrier is provided which can suppress damage of microcarriers in the cell culture process and which can improve the cell culture efficiency. This cell culture microcarrier is provided with substrate particles and a...  
WO/2022/167087A1
The invention provides compounds of formula (I), that are peptidase enhanced cytotoxics. The invention further provides pharmaceutical compositions comprising the compounds, and the use of the compounds or pharmaceutical compositions as ...  
WO/2022/166719A1
A CA4 derivative, a conjugate or pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof in prevention or treatment of cancer. The conjugate can specifically bind to a receptor highly expressed in a tumor...  
WO/2022/167664A1
The present invention relates to the field of compounds intended for the treatment of cancer. Selectivity of these compounds is gained through the presence of a specific tetrapeptidic moiety allowing selective release of the drug. The dr...  
WO/2022/168871A1
Provided is a cell culture microcarrier capable of suppressing aggregation of a microcarrier due to cell clumps and enhancing the efficiency of culturing cells. This cell culture microcarrier is provided with a base particle and a coat...  
WO/2022/162030A1
The present invention therefore relates to peptides of synthetic origin andbiologically active in inhibiting the binding between VEGFR-1 and VEGFR-2receptors and their ligands, and use thereof as a medicament.The use as a medicament of a...  
WO/2022/156693A1
A compound represented by formula I containing an N-(substituted sulfonyl) acetamide structure, a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and an application thereof as a viral protease inhibitor in the prepa...  
WO/2022/156190A1
The present invention provides an antihypertensive peptide, a polyethylene glycol modified antihypertensive peptide, and preparation methods therefor. The antihypertensive peptide of the present invention comprises at least one polypepti...  
WO/2022/149584A1
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention pertains to a peptide in which two or more amino acids are peptide-bonded, wherein at least one of the amino acid residues constit...  
WO/2022/150362A1
Provided herein are compounds and compositions that are reversible agonists of the PDZ3 domain of PSD-95. Methods of their use in treating conditions of neural stress, inflammation, and viability are also provided.  
WO/2022/144293A1
The invention relates to a process for producing readily filterable particles of DL/LD-methionylmethionine, characterized in that a stream of aqueous solution or suspension containing DL/LD-methionylmethionine alkali metal salt is mixed ...  
WO/2022/138891A1
The present invention addresses the problem of providing a method for producing a high-purity peptide compound with high efficiency and high yield. It is found that the problem can be solved by supporting a peptide on a resin for solid-p...  
WO/2022/138953A1
[Problem] To provide a method by which a lipid peptide compound and a salt thereof can be produced with a higher yield and a higher purity than conventional production methods. [Solution] A method for producing a lipid peptide compound r...  
WO/2022/133588A1
The present disclosure provides compounds of formula (I) and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the presen...  
WO/2022/137357A1
The present invention addresses the problem of providing a synthetic culture medium free from animal-derived components. More particularly, the present invention addresses the problem of providing a culture medium that contains a peptide...  
WO/2022/138957A1
[Problem] To provide a practical method for producing a lipidic peptide compound, the method enabling a lipidic peptide compound to be mass produced inexpensively without the need for complicated operations. [Solution] A lipidic peptide ...  
WO/2022/136586A1
The present invention relates to the field of compounds intended for the treatment of cancer. Selectivity of these compounds is gained through the presence of a specific tetrapeptidic moiety allowing selective release of the drug. The dr...  
WO/2022/133069A1
The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for modulating the activity of Matriptase 2 ("Mat-2"), or a mutant thereof. The present disclosure also provides pharmaceutically ac...  
WO/2022/129953A1
P33613WO1 93 ABSTRACT The disclosures herein relate to compounds of Formula (1'): or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders ...  
WO/2022/126275A1
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.  
WO/2022/132603A1
Provided herein are phosphodiesterase 4 (PDE4) degraders, e.g., a compound of Formula (I) or (IA), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or mo...  
WO/2022/119557A1
The present disclosure provides fish-derived peptides with ACE inhibitory activity by hydrolyzing fish meat using the alkaline protease subtilisin, and methods of producing peptide isolates comprising the fish-derived peptides. The prese...  
WO/2022/117590A1
The invention relates to a compound of the general formula I wherein A is selected from the group consisting of an unbranched or branched alkyl group with 1 to 12 carbon atoms, a -R1-O-R2 group, a -R1- Si(R3R4R5) group, a -R1-O-Si(R3R4R5...  
WO/2022/117877A1
The present invention provides cyclic tetrapeptides consisting of alternating α- and β-amino acids and metal complexes thereof. The cyclic tetrapeptides are particularly useful for coordinating a metal selected from Pb, Cd, Hg and As. ...  
WO/2022/112358A2
The present invention relates to a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, for use in a method for preventing or treating an infection by an enveloped virus in an individual.  
WO/2022/114260A1
The present application relates to a peptide having protective activity against cell damage caused by particulate matter, and to uses for the peptide.  
WO/2022/112357A1
The present invention relates to a compound of the following formula (I) in particular for use in a method for preventing or treating a disease in an individual, more particularly for preventing or treating a disease is associated to pro...  
WO/2022/112359A1
The present invention relates to a compound of the following formula (I), or a pharmaceutically acceptable salt thereof, for use in a method for preventing or treating a disease associated to a mutation of the p53 protein in an individual.  
WO/2022/106057A1
According to the present invention there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-QTAV-Z wherei...  
WO/2022/106055A1
According to the present invention, there is provided a tetrapeptide, capable of inducing dermal extracellular matrix protein upregulation, selected from the group consisting of tetrapeptides having the amino acid sequence U-LSXX-Z where...  
WO/2022/106444A1
They have the general Formula X-(Xaa)nLE(Xaa)m-Z wherein Xaa is selected from L, K, E and D, either n=2 and m=0, or n=1 and m=1, at the N-terminal end X being selected from H, -CO-R1, -SO2-R1 or a biotinoyl group, at the C-terminal end Z...  
WO/2022/106712A1
The subject matter of the invention relates to a tetrapeptide which binds to the ZIP9 receptor for the treatment of osteoporosis, myodegenerative diseases, and male infertility. The invention also relates to the use of the tetrapeptide a...  
WO/2022/109335A1
The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable moiety and a second enzymatically cleavable moiety which inc...  
WO/2022/108992A1
A non-radioactive prodrug comprising a PSMA-targeted moiety, a cleavable linker, and an antineoplastic agent capable of selectively killing PSMA-expressing cells and methods of treating a disease or condition associated with PSMA-express...  
WO/2022/106633A1
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...  
WO/2022/106365A1
They have the general Formula X-(Xaa)nPG(Xaa)m-Z wherein Xaa is either A or V, either n=2 and m=0, or n=1 and m=1, at the N-terminal end X being selected from H, -CO-R1, -SO2-R1 or a biotinoyl group, at the C-terminal end Z being selecte...  
WO/2022/106629A1
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...  
WO/2022/106366A1
The tetrapeptide has the general Formula X-LLAN-Z wherein at the N-terminal end X is selected from H, -CO-R1, -SO2-R1 or a biotinoyl group, at the C-terminal end Z is selected from OH, OR1, NH2, NHR1 or NR1R2, and R1 and R2 are selected ...  
WO/2022/099991A1
The present invention belongs to the field of medicine and pharmacy, and provides a polypeptide, a derivative thereof, a hydrogel, and an application in preparing a drug for preventing and/or treating type I diabetes. The present inventi...  
WO/2022/098051A1
The present invention relates to a novel peptide with anti-inflammatory and tissue regeneration actions, and a use thereof.  
WO/2022/092132A1
Provided is a peptide having the following sequence and comprising 3-8 amino acid residues. (I): XmZnPUq Here, P is proline; Z represents an amino acid residue independently selected from lysine (K) and asparagine (N); X represents an ...  
WO/2022/092284A1
[Problem] To provide a new composition capable of preventing adhesion of pollutants by forming a film on the skin or the hair surface and promoting skin penetration as well as preventing the skin and the hair surface from being polluted ...  
WO/2022/090413A1
The present invention relates to peptides and use of said peptides in skin and hair pigmentation. Further, the present invention relates to a composition comprising said peptides for topical delivery.  
WO/2022/082876A1
A c-Met degrading agent based on a targeted protein degradation PROTAC strategy and a preparation method therefor, and the use of such c-Met degrading agents in the treatment of non-small cell lung cancer, gastric cancer and other cancer...  
WO/2022/084747A1
Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anteri...  
WO/2022/084874A1
The present disclosure relates to a cell-laden microgel comprising self-assembly ultrashort peptide (SUP) and a method of frabricating such cell-laden microgels. The present disclosure also relates to a cell microcarrier comprising cell-...  
WO/2022/067445A1
The invention provides a composition comprising one or more bioactive peptides from collagen hydrolysate and use thereof for reducing joint and/or bone pain such as in arthritis or osteoarthritis. The invention also provides a use of the...  

Matches 1 - 50 out of 12,946